Form 4: United Therapeutics EVP Sells Shares After Option Exercise

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), exercised 8,300 stock options at an exercise price of $146.03 per share on March 5, 2026.
• Concurrently, Mahon sold 8,300 shares of common stock in multiple transactions on March 5, 2026, at weighted average prices ranging from $479.4271 to $487.652 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 plan established on August 11, 2025.
• Mahon also acquired 63 shares of common stock on March 4, 2026, through the United Therapeutics Employee Stock Purchase Plan.
• Following these transactions, Mahon directly beneficially owns 36,844 shares of common stock and 33,500 derivative stock options.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the executive's significant share sale, even though it was pre-planned under a 10b5-1 plan. The reduction in direct equity ownership by a key executive can sometimes be interpreted cautiously by investors.

Positives

• The executive acquired 63 shares through the Employee Stock Purchase Plan, indicating continued participation in employee ownership programs.
• The exercise of stock options at $146.03 and subsequent sale at prices significantly higher (ranging from $479.4271 to $487.652) indicates a substantial profit for the executive.

Negatives

• A significant sale of 8,300 shares by a high-ranking executive, even if pre-planned, reduces their direct equity stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market as they can sometimes signal management's perception of future company performance. However, sales executed under a pre-arranged 10b5-1 plan, like this one, are generally viewed with less concern as they are scheduled in advance and not typically reactive to immediate market conditions or non-public information.

Related Party Transactions

• Exercise of stock options and subsequent sale of shares by an executive (Paul A. Mahon) of United Therapeutics Corporation.
• Acquisition of shares by Paul A. Mahon through the United Therapeutics Employee Stock Purchase Plan.

Stakeholder Impact

• Shareholders: The sale by an executive could be interpreted as a slight negative signal, though mitigated by the 10b5-1 plan.
• Employees: The executive's participation in the Employee Stock Purchase Plan shows continued engagement with employee benefit programs.

Key Dates

Recommendation

While the executive's sale of shares reduces their direct equity stake, the transaction was pre-planned under a 10b5-1 plan, which mitigates the immediate negative signal. The executive also acquired shares through an ESPP. Without further financial or operational updates, this Form 4 alone does not warrant a change from a 'hold' position, but investors should monitor future insider activity and company performance.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Paul A. Mahon, 10b5-1 Plan, Employee Stock Purchase Plan